Curaleaf Holdings, Inc. is postponing its previously planned special shareholder meeting to approve a proposed arrangement that includes continuing the company out of British Columbia and domestication in Delaware in the United States. The special meeting will now be combined with Curaleaf’s annual general meeting, expected in the second quarter of 2026.
The company believes holding a combined annual and special meeting will encourage greater shareholder participation, streamline approvals and use resources more efficiently. Curaleaf plans to announce the new meeting date later and will send shareholders an Information Circular, which will also be filed on SEDAR+ and with the SEC.
Curaleaf Holdings, Inc. has scheduled the release of its fourth quarter and full year 2025 financial and operating results for after market close on February 26, 2026. Management will discuss the results on a conference call and webcast that day at 5:00 p.m. ET, followed by a question-and-answer session.
Curaleaf Holdings, Inc. released preliminary, unaudited results for Q4 2025 and announced strategic exits from its hemp business and the state of Missouri. Net revenue for Q4 2025 excluding these discontinued operations is expected to be at least $330 million, implying approximately 4% sequential growth from Q3 2025 net revenue of $317.8 million and about 1% growth versus Q4 2024 net revenue of $327.8 million, above the prior guidance of low single digit growth.
Fourth quarter adjusted gross profit margin excluding the discontinued businesses is anticipated to be about 48.5%, in line with Q4 2024, and full year 2025 adjusted gross margin is expected to be around 50%. Management is discontinuing the hemp division following U.S. federal legislation reducing permitted hemp-derived THC content to 0.3% and exiting Missouri due to sub-scale operations; together these units contributed roughly $2 million of revenue across Q3 and Q4 2025. The company also highlighted plans to complete refinancing of its senior secured notes due December 2026 and expects to release full Q4 and full-year 2025 results by early March.
Curaleaf Holdings, Inc. filed a Form 6-K furnishing its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and nine months ended September 30, 2025, together with comparative information as of December 31, 2024.
The submission includes CEO and CFO certifications of interim filings and a press release dated November 5, 2025. Exhibit 99.1 is incorporated by reference into Curaleaf’s Registration Statement on Form F-10 (File No. 333-269109).